阿德瑪生物(納斯達克：ADMA-GET評級)和石墨生物(納斯達克：GRPH-GET評級)都是小盤醫療公司，但哪一家更好？我們將根據這兩家公司的股息、收益、盈利能力、估值、分析師建議、機構所有權和風險等方面的實力進行比較。
熱門資訊> 正文
納斯達克(Tmall：GRPH)和阿迪瑪生物科技(納斯達克：ADMA)
2022-07-06 15:21
ADMA Biologics (NASDAQ:ADMA – Get Rating) and Graphite Bio (NASDAQ:GRPH – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.
Valuation & Earnings
估值與收益
Get
到達
ADMA Biologics
ADMA生物製品
alerts:
警報：
This table compares ADMA Biologics and Graphite Bio's revenue, earnings per share (EPS) and valuation.
此表比較了ADMA Biologics和Graphite Bio的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ADMA Biologics | $80.94 million | 5.16 | -$71.65 million | ($0.50) | -4.26 |
| Graphite Bio | N/A | N/A | -$70.76 million | ($4.56) | -0.66 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| ADMA生物製品 | 8094萬美元 | 5.16 | -7,165萬元 | ($0.50) | -4.26 |
| 石墨生物 | 不適用 | 不適用 | -7076萬美元 | ($4.56) | -0.66 |
Graphite Bio has lower revenue, but higher earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Graphite Bio, indicating that it is currently the more affordable of the two stocks.
石墨生物的收入低於ADMA生物，但收益高於ADMA生物。ADMA Biologics的市盈率低於Graphite Bio，表明它目前是兩隻股票中更負擔得起的一隻。
Analyst Recommendations
分析師建議
This is a summary of recent ratings and recommmendations for ADMA Biologics and Graphite Bio, as reported by MarketBeat.
據MarketBeat報道，這是對ADMA生物製品和石墨生物最近評級和推薦的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ADMA Biologics | 0 | 0 | 4 | 1 | 3.20 |
| Graphite Bio | 0 | 2 | 5 | 0 | 2.71 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| ADMA生物製品 | 0 | 0 | 4 | 1 | 3.20 |
| 石墨生物 | 0 | 2 | 5 | 0 | 2.71 |
ADMA Biologics currently has a consensus target price of $5.70, suggesting a potential upside of 167.61%. Graphite Bio has a consensus target price of $17.00, suggesting a potential upside of 468.56%. Given Graphite Bio's higher possible upside, analysts plainly believe Graphite Bio is more favorable than ADMA Biologics.
ADMA Biologics目前的共識目標價為5.7美元，暗示潛在上行167.61%。石墨生物的一致目標價為17美元，暗示潛在上漲468.56%。考慮到Graphite Bio更有可能的上行空間，分析師們顯然認為Graphite Bio比ADMA Biologics更有利。
Institutional & Insider Ownership
機構與內部人持股
55.2% of ADMA Biologics shares are owned by institutional investors. Comparatively, 59.9% of Graphite Bio shares are owned by institutional investors. 5.9% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
ADMA Biologics 55.2%的股份由機構投資者持有。相比之下，機構投資者持有Graphite Bio 59.9%的股份。ADMA Biologics 5.9%的股份由內部人士持有。強大的機構持股表明，對衝基金、捐贈基金和大型基金管理公司相信，一家公司的長期表現將好於大盤。
Profitability
盈利能力
This table compares ADMA Biologics and Graphite Bio's net margins, return on equity and return on assets.
此表比較了ADMA Biologics和Graphite Bio的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| ADMA Biologics | -83.27% | -59.36% | -27.13% |
| Graphite Bio | N/A | -20.17% | -19.42% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| ADMA生物製品 | -83.27% | -59.36% | -27.13% |
| 石墨生物 | 不適用 | -20.17% | -19.42% |
Summary
摘要
Graphite Bio beats ADMA Biologics on 8 of the 13 factors compared between the two stocks.
在兩隻股票的13個指標中，石墨生物公司有8個指標超過了ADMA生物公司。
ADMA Biologics Company Profile (Get Rating)
ADMA生物製品公司簡介(獲取評級)
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
ADMA生物製藥公司是一家生物製藥公司，致力於在美國和國際上開發、製造和銷售用於治療免疫缺陷和傳染病的特種血漿衍生生物製劑。它提供BIVIGAM，一種靜脈免疫球蛋白(IVIG)產品，用於治療原發性體液免疫缺陷(PI)；ASCENIV，一種IVIG產品，用於治療PI；以及NaBI-HB，用於治療急性暴露於含有乙肝表面抗原的血液和其他列出的乙肝暴露。該公司還開發一系列血漿衍生療法，包括與治療和預防免疫球蛋白肺炎沙門氏菌感染方法有關的產品。此外，它還運營來源血漿收集設施。該公司通過獨立分銷商、銷售代理、專業藥店和其他替代網站提供商銷售其產品。ADMA Biologics，Inc.成立於2004年，總部位於新澤西州拉姆齊。
Graphite Bio Company Profile (Get Rating)
石墨生物公司簡介(獲取評級)
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
石墨生物公司是一家臨牀階段的基因編輯公司，在美國致力於開發嚴重和危及生命的疾病的治療方法。它提供了GPH101，這是一種經過基因編輯的自體造血干細胞候選產品，可以直接糾正導致鐮狀細胞疾病的突變並恢復正常的成人血紅蛋白表達；GPH201，用於治療X連鎖嚴重聯合免疫缺陷綜合徵；以及GPH301，用於治療高謝病，這是一種導致葡萄糖腦苷酶缺乏的遺傳性疾病。該公司前身為Integral Medicines，Inc.，並於2020年8月更名為Graphite Bio，Inc.。石墨生物公司成立於2017年，總部位於加利福尼亞州舊金山南部。
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ADMA生物製品日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ADMA Biologics和相關公司的最新新聞和分析師評級的每日簡要摘要。
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
